Comparison the Effect of Interval, Continuous and combined Aerobic Exercise on Liver Enzymes and Metabolic Syndrome in Overweight Type 2 Diabetic Patients with Nonalcoholic Fatty Liver

Comparison the Effect of Interval, Continuous and combined Aerobic Exercise on Liver Enzymes, IGF-1 and Insulin Hormone and Metabolic Syndrome in Overweight Type 2 Diabetic Patients with Nonalcoholic Fatty Liver

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110527006611N3

Enrollment

Registered

2019-11-12

Start date

2018-10-23

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes- Non-alcoholic fatty liver disease. K76.0: Nonalcoholic fatty liver disease [NAFLD]-E11: Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: interval aerobic exercise - The interval aerobic exercise group performed exercise on a stationary bike for two months, three days a week, with an intensity of 75

Eligibility

Sex/Gender

Female

Age

40 Years to 55 Years

Inclusion criteria

Inclusion criteria: Subjects are type 2 diabetic women with non-alcoholic fatty liver. They are non-insulin-dependent They use oral medications for treatment (glibenclamide and metformin and sulfonylurease). The maximum blood glycosylated hemoglobin is 11%. The minimum history of diabetes is 1 year and the maximum history of diabetes is 15 years

Exclusion criteria

Exclusion criteria: Patients have retinopathy, nephropathy and severe neuropathy. Have a history of cardiovascular disease and musculoskeletal disorders Severe musculoskeletal problems that restrict physical activity

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase enzyme. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Aspartate Aminotransferase enzyme. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Alkaline phosphatase enzyme. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Glycosylated hemoglobin. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with Pishtaz Teb kit.;HDL Cholesterol. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;LDL Cholesterol. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Cholesterol. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Triglyceride. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Waist circumference. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Standard tape meter.;Blood Pressure. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: brachial digital blood pressure monitor.;Fasting blood glucose. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with Bio	—

Measure

Time frame

Alanine Aminotransferase enzyme. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Aspartate Aminotransferase enzyme. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Alkaline phosphatase enzyme. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Glycosylated hemoglobin. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with Pishtaz Teb kit.;HDL Cholesterol. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;LDL Cholesterol. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Cholesterol. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Triglyceride. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with BioSystems kit.;Waist circumference. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Standard tape meter.;Blood Pressure. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: brachial digital blood pressure monitor.;Fasting blood glucose. Timepoint: At the beginning of the study (before the intervention) and two months after the intervention. Method of measurement: Blood test with Bio

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Bayat

The University of Tehran

z.bayat@ut.ac.ir00987644433661-2

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026